Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis

Annals of the Rheumatic Diseases

Volumn 74, Issue 3, 2015, Pages 564-568

  Westhovens, Rene ^a,o   Robles, Manuel ^b   Ximenes, Antonio Carlos ^c   Wollenhaupt, Jurgen ^d   Durez, Patrick ^e   Gomez Reino, Juan ^f   Grassi, Walter ^g   Haraoui, Boulos ^h   Shergy, William ⁱ   Park, Sung Hwan ^j   Genant, Harry ^k   Peterfy, Charles ^l   Becker, Jean Claude ^m   Murthy, Bindu ⁿ  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Centro Medico Toluca   (Mexico)

^c HOSPITAL GERAL DE FORTALEZA   (Brazil)

^d Schoen Klinik   (Germany)

^e CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^f Instituto de Salud Carlos III   (Spain)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h Institut de Rhumatologie de Montreal   (Canada)

ⁱ UNIVERSITY OF ALABAMA IN HUNTSVILLE   (United States)

^j The Catholic University of Korea   (South Korea)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l Spire Sciences Inc   (United States)

^m Becker Clinical Research Consulting LLC   (United States)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; STEROID; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; APPENDICITIS; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CLAW TOE; CONTROLLED STUDY; DAS28; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOCARDITIS; EPISCLERITIS; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OSTEOARTHRITIS; PLEURISY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; STEADY STATE; TOE MALFORMATION; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME;

ABATACEPT; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOCONJUGATES; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84922367251     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206149     Document Type: Article

References (21)

1. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
2. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
3. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
4. Detert J, Bastian H, Listing J, et al. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann Rheum Dis 2013;72:844-50.
5. Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 2013;71:351-7.
6. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
7. Verschueren P, Westhovens R. Optimal care for early RA patients: the challenge of translating scientific data into clinical practice. Rheumatology (Oxford) 2011;50:1194-200.
8. Tanaka Y, Hirata S, Saleem B, et al. Discontinuation of biologics in patients with rheumatoid arthritis. Clin Exp Rheumatol 2013;31:S22-7.
9. Huizinga T, Donka T, Conaghan P, et al. Clinical and radiographic outcomes at two years and the effect of tocilizumab discontinuation following sustained remission in the second year of the ACT-RAY study. Ann Rheum Dis 2013; 72(Suppl 3):63.
10. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 2013;381:918-29.
11. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013;72:64-71.
12. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
13. van den Broek M, Klarenbeek NB, Dirven L, et al. Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study. Ann Rheum Dis 2011;70:1389-94.
14. Emery P, Spieler W, Stopinska-Polaszewska M, et al. Assessing maintenance of remission after withdrawal of etanercept plus methotrexate, methotrexate alone, or placebo in early rheumatoid arthritis patients who achieved remission with etanercept and methotrexate: The Prize study. Arthritis Rheum 2013;65(Suppl 10):2689.
15. Emery P, Burmester G, Bykerk V, et al. Induction of clinical remission followed by drug-free withdrawal with abatacept combination and monotherapy in early RA: results from the AVERT study Over 18 months. Ann Rheum Dis 2014;73 (Suppl 2).
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis 2010;69:510-16.
18. Ma Y, Lin BR, Lin B, et al. Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin 2009;30:364-71.
19. Orencia Prescribing Information. 2013. http://packageinserts.bms.com/pi/pi-orencia.pdf (last accessed: 28 Sept 2014).
20. Davis P, Nadler S, Rouleau K, et al. Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes. Arthritis Res Ther 2005;7 (Suppl 1):P21.
21. Westhovens R, Kremer J, Emery P, et al. Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study. Clin Exp Rheumatol 2014;32:553-62.